Financial Daily from THE HINDU group of publications
Saturday, Feb 08, 2003

News
Features
Stocks
Port Info
Archives

Group Sites

Industry & Economy - Bio-tech & Genetics


Australian biotech cos keen on joint ventures

P.T. Jyothi Datta

NEW DELHI, Feb. 7

THE Australian biotech industry, estimated to be over A$1 billion, is keen on forging an alliance with its Indian counterparts in terms of manufacturing, clinical trials and joint research and development.

Dr Peter Riddles, Director and President, AusBiotech Ltd (the apex body for the Australian biotech industry), told Business Line that Australian companies were strong on the R&D front and were looking for partners in manufacturing and clinical trials. About 38 per cent of the Australian biotech activity is in the pharmaceutical and therapeutic segments and about 10 per cent is in agriculture, he pointed out.

On the worldwide debate in favour of biotech pharma products and against genetically modified food, he said biotechnology across the board was gaining acceptance in Australia, since the Government had put in place a regulatory framework to monitor the products that went into the market.

Like other multinationals looking to set up shop in India, intellectual property rights issues are a prime concern with Australian biotech firms too, points out Mr Chris Gibson, Major Projects Manager, Isonet, a non-profit organisation financially supported by the Government to facilitate Australian manufacturers in doing business abroad. Echoing his sentiments, Dr Riddles pointed out that tighter and transparent norms would help instil faith in companies wanting to do business.

Further, he pointed out that Indian companies had also sought help in commercialisation of their R&D efforts. Interestingly, AusBiotech, formerly the Australian Biotechnology Association, also facilitates the commercialisation of Australian bioscience in the international marketplace.

Australian firms doing business in India include JRH biosciences and Gribbles. JRH manufactures and markets a range of products for cell culture, research, immunohematology and human diagnostics. The range is supplied to local and international research institutions, universities, biotechnology and pharmaceutical companies, hospitals and pathology laboratories. Gribbles has a joint venture company with Dr Reddy's Laboratories to set up a network of path-labs in India.

Trade Minister to visit India

Though it may take some time before preliminary discussions between companies fructify into a formal alliance, Ms Elizabeth Sullivan, representing the Australian Trade Commission, said it had strengthened Indo-Australian ties.

Article E-Mail :: Comment :: Syndication

Stories in this Section
IIT-Kharagpur unit targets Rs 40-cr revenue


Watch this match on TV: Budget versus cricket
GDP growth to fall to 4.4 pc — This fiscal worst for farm sector since 1979-80
Fiscal consolidation remains a distant dream
Salary expenditure exceeds AP State revenue, say experts
Time to formulate internal trade policy
Non-Plan expenditure goes up — Govt unable to gain from drop in borrowings cost
ADA to seek 40 more GE engines for LCA
BHPV heat exchangers for LCA
French business council spots fresh investment avenues
China creates data bank to promote trade
India takes up market issue with French team
`States should do more to develop SEZs'
Gujarat crude royalty jumps to Rs 850 cr
Cabinet to take up power Bill on Feb 11
Protesters' bid to thwart ADB talks
India tops in sponge iron production — Accounts for 12 pc of global output
Textile Corpn aiming for profit by year-end
More ripples likely in bottled water; BIS to review norms
UK co to tap IFC for funding NGO schools
A/c industry for separate body to test energy efficiency
Gem exporters resent seizures of stock-in-trade
HDFC property exhibition
Australian biotech cos keen on joint ventures
No decision yet on RINL sell-off
A helping hand to the disabled
AP tops in Girijan welfare funds use
Dubai Internet City woos software firms


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line